Daily Newsletter

30 August 2024

Daily Newsletter

30 August 2024

FDA approves Jupiter Endovascular’s pivotal study for PE treatment

The Vertex system utilises the Endoportal Control technology to enhance precision in catheter-based interventions.

Archana Rani August 30 2024

The US Food and Drug Administration (FDA) has granted approval for Jupiter Endovascular’s investigational device exemption (IDE) application filed for the SPIRARE II US pivotal study of its Vertex pulmonary embolectomy system to treat acute pulmonary embolism (PE).

This system utilises the company's Endoportal Control technology to enhance precision in catheter-based interventions.

The prospective, single-arm SPIRARE II trial is designed to evaluate the Vertex system in treating patients with acute PE.

It will enrol up to 145 patients across approximately 25 US sites, aiming to demonstrate the procedural and clinical benefits of the new technology.

As part of the study, the company will assess the Vertex system's impact on right heart function and patient outcomes up to 30 days post-procedure.

The Endoportal Control platform is a significant innovation in endovascular procedures, allowing for more stable and precise treatment delivery.

The device is navigated to the target area flexibly before being pressurised to remain fixed during the procedure and finally relaxed for repositioning or removal.

This pivotal study is part of Jupiter Endovascular's broader SPIRARE clinical programme, including the European-based SPIRARE I trial.

Jupiter Endovascular CEO Carl St Bernard said: “We are excited about FDA approval of the first pivotal study of a system leveraging our Endoportal Control platform technology. In the more than 25 animal studies conducted to date with the technology, it has demonstrated safe and easy navigation through the heart and vasculature and effective delivery of test interventions.

“Endoportal Control has the potential to meaningfully improve many endovascular procedures while enabling entirely new therapies. Our Vertex system for pulmonary embolectomy is the first of what we intend to be a portfolio of our own interventional procedure systems incorporating Endoportal Control to treat a variety of cardiovascular conditions that affect millions of patients worldwide.”

Earlier this month, Jupiter Endovascular emerged from stealth with $21m in new financing as it looks to forge its new type of endovascular procedure.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close